leadf
logo-loader
viewbit bio

bit bio unveils new executive team following rebrand

The company is aiming to commercialise Opti-OX, a technology to efficiently and consistently reprogram human stem cells for research, drug discovery and cell therapies

Horizon Discovery Group PLC - bit bio unveils new executive team following rebrand
Chief scientific adviser Roger Pedersen is a co-founder of the Cambridge Stem Cell Institute

bit bio has unveiled a new executive team following its rebranding from Elpis Biomed in October.

The biotech, which specialises in coding and reprogramming stem cells, is now headed by chief executive Mark Kotter, a stem cell biologist and neurosurgeon at the University of Cambridge, while Florian Schuster, the former finance boss of Tessa Therapeutics, is taking up the positions of chief financial and chief operations officer.

The firm’s chief business officer, meanwhile, is Paul Morrill, the co-founder of gene editing firm Horizon Discovery Group PLC (LON:HZD), with immune-oncology clinician Ramy Ibrahim and stem cell reprogramming specialist Marius Wernig serving as scientific advisors.

Ibrahim and Wernig join chief scientific adviser Roger Pedersen, a thought leader in stem cell biology and a co-founder of the Cambridge Stem Cell Institute.

The company is aiming to commercialise Opti-OX, a technology to efficiently and consistently reprogram human stem cells for research, drug discovery and cell therapy.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of bit bio named herein, including the promotion by the Company of bit bio in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Elpis BioMed applying its 'disruptive' technology to produce human cells at...

Mark Kotter, founder of Elpis BioMed Ltd, tells Proactive the company was spun-out of Cambridge University and is built around technology which allows you to produce human cells at scale. ''These are very important in the context of drug discovery, biomedical research and also cell...

on 27/7/18

2 min read